ANI Pharmaceuticals, Inc. ANIP · NASDAQ
$72.67 +0.15% (+$0.11)
Summary
79 / 100 · Bulios Score
What speaks for it
- Revenue grew by 41% a year over the last 3 years.
- It holds more cash than debt: $360.2M against $330.3M.
- The share price is below the Bulios Fair Price.
- Analysts expect revenue to grow by 25% this fiscal year.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 33% a year over 5 years. Over the last 3 years it grew by 41% a year. For the next fiscal year analysts expect revenue to grow by 25%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 35 USD
- Research and development 5.1 USD
- Sales and administration 45 USD
- Taxes and other 4.5 USD
- Net profit 11 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.1 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 4
- Sell 0
Today's price within the analysts' price targets
The average target of $99.5 is 37% above today's price. 60% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Sales of rare disease pharmaceutical products 48%
- Total Sales of Generics and Other 45%
- Sales of Established Brands 6.9%
By region
- UNITED STATES 96%
- Non-US 3.5%
Sales of rare disease pharmaceutical products brings in 48% of revenue.
Segments in detail